Enoxaparin

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

28 Suppliers, 14 USDMF, 3 CEP/COS, 1 EU WC, 2 KDMF, 6 NDC API, 15 Listed Suppliers

DEVELOPMENTS

7 Drug(s) in Development

7 Drug(s) in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Exports, FDF Imports

INTERMEDIATES

2 Suppliers

2 Suppliers

DOSSIERs // Finished Dosage Forms

250 Dossiers, 62 FDA Orange Book, 50 Europe, 37 Canada, 26 Australia, 10 South Africa, 65 Listed Dossiers

DRUG PRODUCT COMPOSITION

INJECTABLE;SUBCUTANEOUS - 100MG/ML (100MG/ML), INJECTABLE;SUBCUTANEOUS - 120MG/0.8ML (150MG/ML), INJECTABLE;SUBCUTANEOUS - 150MG/ML (150MG/ML), INJECTABLE;INTRAVENOUS, SUBCUTANEOUS - 300MG/3ML (100MG/ML), INJECTABLE;SUBCUTANEOUS - 30MG/0.3ML (100MG/ML), INJECTABLE;SUBCUTANEOUS - 40MG/0.4ML (100MG/ML), INJECTABLE;SUBCUTANEOUS - 60MG/0.6ML (100MG/ML), INJECTABLE;SUBCUTANEOUS - 80MG/0.8ML (100MG/ML), INJECTABLE;SUBCUTANEOUS - 90MG/0.6ML (150MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

Suppliers, 1 Nanjing Well Pharmaceutical, 1 Actylis, 1 Finar

EXCIPIENTS BY APPLICATIONS

2 Topical, 1 Parenteral, 1 Solubilizers

GLOBAL SALES INFORMATION

16 US Medicaid Prescriptions, 55 Finished Drug Prices

MARKET PLACE

36 APIs, 67 DOSSIERS // FDF

PATENTS

4 Health Canada Patents

4 Health Canada Patents

ANALYTICAL SOLUTION(s)

1 EDQM Standards, 7 USP Standards, 4 Other Ref. Standards

DIGITAL CONTENT

3 Data Compilation & Company Tracker #PharmaFlow, 31 News

Information, Expiry & Status of Health Canada Patents covering Enoxaparin.

Enoxaparin

Synopsis

Chemistry

APIs // Active Pharmaceutical Ingredients

28 Suppliers

14 USDMF

3 CEP/COS

1 EU WC

2 KDMF

6 NDC API

15 Listed Suppliers

DEVELOPMENTS

7 Drug(s) in Development

PRICE INFORMATION

API Reference Price

API Exports

API Imports

FDF Exports

FDF Imports

INTERMEDIATES

2 Suppliers

DOSSIERs // Finished Dosage Forms

250 Dossiers

62 FDA Orange Book

50 Europe

37 Canada

26 Australia

10 South Africa

65 Listed Dossiers

DRUG PRODUCT COMPOSITION

INJECTABLE;SUBCUTANEOUS - 100MG/ML (100MG/ML)

INJECTABLE;SUBCUTANEOUS - 120MG/0.8ML (150MG/ML)

INJECTABLE;SUBCUTANEOUS - 150MG/ML (150MG/ML)

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS - 300MG/3ML (100MG/ML)

INJECTABLE;SUBCUTANEOUS - 30MG/0.3ML (100MG/ML)

INJECTABLE;SUBCUTANEOUS - 40MG/0.4ML (100MG/ML)

INJECTABLE;SUBCUTANEOUS - 60MG/0.6ML (100MG/ML)

INJECTABLE;SUBCUTANEOUS - 80MG/0.8ML (100MG/ML)

INJECTABLE;SUBCUTANEOUS - 90MG/0.6ML (150MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

Suppliers

1 Nanjing Well Pharmaceutical

1 Actylis

1 Finar

EXCIPIENTS BY APPLICATIONS

2 Topical

1 Parenteral

1 Solubilizers

GLOBAL SALES INFORMATION

16 US Medicaid Prescriptions

55 Finished Drug Prices

MARKET PLACE

36 APIs

67 DOSSIERS // FDF

PATENTS

4 Health Canada Patents

ANALYTICAL SOLUTION(s)

1 EDQM Standards

7 USP Standards

4 Other Ref. Standards

DIGITAL CONTENT

3 Data Compilation & Company Tracker #PharmaFlow

31 News

100mg/ml (30mg/0.3ml)

Solution

Human

2011-06-25

2002-07-30

1991-06-25

LOVENOX

Subcutaneous

100mg/ml (40mg/0.4ml,60mg/0.6ml,80mg/0.8ml & 100mg